Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Research and development, net	$ (1,612)	$ (1,953)	$ (4,594)	$ (5,852)
General and administrative	(932)	(1,521)	(3,193)	(4,361)
Operating loss	(2,544)	(3,474)	(7,787)	(10,213)
Financing income, net	98	6	201	43
Net loss	$ (2,446)	$ (3,468)	$ (7,586)	$ (10,170)
Basic net loss per share	$ (0.21)	$ (0.49)	$ (0.79)	$ (1.43)
Diluted net loss per share	$ (0.21)	$ (0.49)	$ (0.79)	$ (1.43)
Basic weighted average common shares outstanding	11,707,317	7,108,133	9,653,337	7,108,133
Diluted weighted average common shares outstanding	11,707,317	7,108,133	9,653,337	7,108,133